skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Orantinib (Code C1884)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Orantinib

Definition: An orally bioavailable receptor tyrosine kinase inhibitor. SU6668 binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. SU6668 also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. (NCI04)

NCI-GLOSS Definition: A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called angiogenesis inhibitors.

Display Name: Orantinib

Label: Orantinib

NCI Thesaurus Code: C1884 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0960373  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
3-(2,4-Dimethyl-5-((2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-1H-pyrrol-3-yl)propionic Acid
SU 6668
Sugen SU6668
TSU 68

External Source Codes: 
CAS Registry Number 252916-29-3 (see NLM ChemIDplus info)
FDA UNII Code 9RL37ZZ665
NSC Code 702827 (see NCI DTP info)
PDQ Closed Trial Search ID 38421
PDQ Open Trial Search ID 38421 (check for NCI PDQ open clinical trial info)
UMLS CUI C0960373

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C18H18N2O3
code C1884
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name SU6668
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: Yes  


Mainbox Bottom